Transparent Thinking Blog

TrialAssure cubes divider
GenAI That Works: How Partnerships Outperform Internal Builds in Pharma | TrialAssure

Why Internal GenAI Builds in Pharma Often Fall Short

Read More
Building a Data Sharing Mindset with 5 Steps to Streamline Anonymization Early in Clinical Trials TrialAssure

Building a Data Sharing Mindset with 5 Steps to Streamline Anonymization Early in Clinical Trials 

Read More
DIA Europe 2025

AI Takes Center Stage at DIA Europe 2025 in Basel

Read More
A Clear Path to Successful AI Adoption in Medical Writing with Structured GenAI Pilots

Upcoming Webinar: A Clear Path to Successful AI Adoption in Medical Writing with Structured GenAI Pilots

Read More
TrialAssure and Certara Anonymisation Technology Tool Partnership

How Certara and TrialAssure Partner to Deliver Faster, Compliant Anonymisation for Global Sponsors

Read More
The Ultimate Guide to Anonymization or Redaction of Documents: Strategies, Workflow, and Mindset

TrialAssure Releases Comprehensive Guide to Anonymization and Redaction Whitepaper for Free Download

Read More
Modernizing Federal Technology for a More Connected and Efficient Government | TrialAssure | missing clinical trial results FDA

Modernizing Federal Technology for a More Connected and Efficient Government

Read More
EMA Policy 0070, EMA’s New Transparency Rules: Don’t Be Caught Late or in Violation 

EMA’s New Transparency Rules: Don’t Be Caught Late or in Violation 

Read More
GenAI to create Informed Consent Forms (ICFs)

How MMS and TrialAssure Engaged AI to Improve the Quality and Delivery in Producing Informed Consent Forms (ICFs) and other Regulatory Documents

Read More
The following is a case study based on real work conducted between TrialAssure and one of its trusted sponsor partners. Problem  A clinical stage biotech company, sought to share their clinical trial datasets voluntarily with research partners for secondary analyses and derivative research. However, they faced significant challenges, including the high risk of re-identification due to a small patient population that makes traditional qualitative anonymization insufficient. Additionally, they needed to protect patient privacy while preserving the data's utility for meaningful research, as well as maintain compliance with varying global regulatory requirements.   To address these complexities, they sought an experienced partner capable of delivering quantitative, evidence-based anonymization.  Solution  TrialAssure, with its industry-leading AI-powered platform ANONYMIZE, was selected as the ideal partner to meet these challenges. Leveraging over a decade of experience in clinical data transparency and anonymization, TrialAssure delivered a comprehensive solution tailored to their needs, starting with a risk-based anonymization approach.  TrialAssure ANONYMIZE employed a sophisticated quantitative anonymization strategy to achieve measurable re-identification risk thresholds while maintaining optimal data utility. Through TrialAssure’s quick and efficient processes, the end-to-end project, encompassing risk analysis, anonymization, and reporting, was completed approximately 80 percent faster.   On top of the anonymized dataset, TrialAssure provided a detailed Data Anonymization Report and Data Specification Report to ensure visibility into the anonymization process, support informed decision-making, and demonstrate compliance with regulatory standards. Additionally, TrialAssure ANONYMIZE acted as a secure data exchange platform, enabling seamless and protected data sharing with the clinical-stage biotech’s research partners.

How a Clinical-Stage Biotech Accelerated Secure Clinical Trial Data Sharing 80% Faster with TrialAssure 

Read More
Get in Touch

Looking to streamline your clinical trial disclosure and transparency efforts?

TrialAssure is ready to help your organization embark on a Transparency Transformation!

To learn more about the TrialAssure Transparency Suite, specific products, or our company, contact us below.

Yes, please send me more information about TrialAssure.